Tributary Capital Management LLC Acquires New Stake in Prestige Consumer Healthcare Inc. $PBH

Key Points

• Tributary Capital Management LLC has acquired a new stake in Prestige Consumer Healthcare Inc., purchasing 147,441 shares valued at approximately $11.8 million during the second quarter.
• Prestige Consumer Healthcare reported earnings per share (EPS) of $0.95 for the most recent quarter, falling short of analyst estimates by $0.06, with quarterly revenue also down 6.6% year-over-year.
• Currently, 99.95% of Prestige Consumer Healthcare's stock is owned by hedge funds and institutional investors, indicating a strong interest from large financial players.

Tributary Capital Management LLC acquired a new stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 147,441 shares of the company's stock, valued at approximately $11,773,000. Tributary Capital Management LLC owned about 0.30% of Prestige Consumer Healthcare as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in PBH. GAMMA Investing LLC lifted its position in Prestige Consumer Healthcare by 35.9% during the first quarter. GAMMA Investing LLC now owns 1,879 shares of the company's stock worth $162,000 after buying an additional 496 shares during the period. Bessemer Group Inc. lifted its position in Prestige Consumer Healthcare by 22.7% during the first quarter. Bessemer Group Inc. now owns 361,958 shares of the company's stock worth $31,118,000 after buying an additional 66,908 shares during the period. KBC Group NV lifted its position in Prestige Consumer Healthcare by 7.4% during the first quarter. KBC Group NV now owns 2,199 shares of the company's stock worth $189,000 after buying an additional 151 shares during the period. Meritage Portfolio Management lifted its position in Prestige Consumer Healthcare by 6.8% during the first quarter. Meritage Portfolio Management now owns 13,702 shares of the company's stock worth $1,178,000 after buying an additional 876 shares during the period. Finally, Principal Financial Group Inc. lifted its position in Prestige Consumer Healthcare by 3.2% during the first quarter. Principal Financial Group Inc. now owns 264,817 shares of the company's stock worth $22,766,000 after buying an additional 8,291 shares during the period. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $63.37 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. Prestige Consumer Healthcare Inc. has a 1 year low of $60.15 and a 1 year high of $90.04. The firm has a market cap of $3.12 billion, a P/E ratio of 14.87, a price-to-earnings-growth ratio of 1.98 and a beta of 0.44. The stock has a 50-day simple moving average of $64.16 and a 200-day simple moving average of $74.93.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The company had revenue of $249.53 million during the quarter, compared to analyst estimates of $260.71 million. During the same quarter last year, the business posted $0.90 EPS. Prestige Consumer Healthcare's quarterly revenue was down 6.6% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. On average, equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

PBH has been the topic of several recent analyst reports. Weiss Ratings reiterated a "hold (c)" rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Zacks Research downgraded Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research report on Thursday, September 4th. Canaccord Genuity Group cut their price objective on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Oppenheimer cut their price objective on Prestige Consumer Healthcare from $82.00 to $72.00 and set an "outperform" rating on the stock in a report on Tuesday. Finally, Sidoti upgraded Prestige Consumer Healthcare from a "neutral" rating to a "buy" rating and set a $80.00 price objective on the stock in a report on Wednesday, September 24th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $90.60.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.